- Home
- FHB vs RARE Comparison
FHB vs RARE Comparison
Compare FHB & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FHB
- RARE
- Stock Information
- Founded
- FHB 1858
- RARE 2010
- Country
- FHB United States
- RARE United States
- Employees
- FHB N/A
- RARE N/A
- Industry
- FHB Major Banks
- RARE Biotechnology: Pharmaceutical Preparations
- Sector
- FHB Finance
- RARE Health Care
- Exchange
- FHB Nasdaq
- RARE Nasdaq
- Market Cap
- FHB 2.9B
- RARE 3.3B
- IPO Year
- FHB 2016
- RARE 2014
- Fundamental
- Price
- FHB $23.34
- RARE $37.14
- Analyst Decision
- FHB Sell
- RARE Strong Buy
- Analyst Count
- FHB 8
- RARE 15
- Target Price
- FHB $26.75
- RARE $90.53
- AVG Volume (30 Days)
- FHB 700.0K
- RARE 1.2M
- Earning Date
- FHB 07-25-2025
- RARE 07-31-2025
- Dividend Yield
- FHB 4.46%
- RARE N/A
- EPS Growth
- FHB 5.75
- RARE N/A
- EPS
- FHB 1.84
- RARE N/A
- Revenue
- FHB $794,296,000.00
- RARE $590,689,000.00
- Revenue This Year
- FHB $9.70
- RARE $18.94
- Revenue Next Year
- FHB $3.41
- RARE $28.93
- P/E Ratio
- FHB $12.69
- RARE N/A
- Revenue Growth
- FHB N/A
- RARE 33.46
- 52 Week Low
- FHB $19.89
- RARE $29.59
- 52 Week High
- FHB $28.80
- RARE $60.37
- Technical
- Relative Strength Index (RSI)
- FHB 45.10
- RARE 52.29
- Support Level
- FHB $22.91
- RARE $36.01
- Resistance Level
- FHB $24.25
- RARE $40.19
- Average True Range (ATR)
- FHB 0.45
- RARE 1.47
- MACD
- FHB -0.10
- RARE 0.06
- Stochastic Oscillator
- FHB 25.98
- RARE 49.92
About FHB First Hawaiian Inc.
First Hawaiian Inc is a bank holding company. It provides a diversified range of banking services to consumer and commercial customers, including deposit products, lending services, and wealth management and trust services. The company offers a variety of deposit products to its customers, including checking and savings accounts and other types of deposit accounts. It provides commercial and industrial lending, including auto dealer flooring, commercial real estate, and construction lending. It also offers comprehensive consumer lending services focused on residential real estate lending, indirect auto financing, and other consumer loans. The company's segments are Retail Banking, Commercial Banking, and Treasury, and others of which key revenue is derived from Retail Banking.
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.